1. Home
  2. CGON vs RNG Comparison

CGON vs RNG Comparison

Compare CGON & RNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • RNG
  • Stock Information
  • Founded
  • CGON 2010
  • RNG 1999
  • Country
  • CGON United States
  • RNG United States
  • Employees
  • CGON N/A
  • RNG N/A
  • Industry
  • CGON
  • RNG EDP Services
  • Sector
  • CGON
  • RNG Technology
  • Exchange
  • CGON NYSE
  • RNG Nasdaq
  • Market Cap
  • CGON 2.1B
  • RNG 2.3B
  • IPO Year
  • CGON 2024
  • RNG 2013
  • Fundamental
  • Price
  • CGON $26.90
  • RNG $29.55
  • Analyst Decision
  • CGON Strong Buy
  • RNG Buy
  • Analyst Count
  • CGON 10
  • RNG 15
  • Target Price
  • CGON $64.44
  • RNG $34.00
  • AVG Volume (30 Days)
  • CGON 864.2K
  • RNG 1.2M
  • Earning Date
  • CGON 08-07-2025
  • RNG 07-31-2025
  • Dividend Yield
  • CGON N/A
  • RNG N/A
  • EPS Growth
  • CGON N/A
  • RNG N/A
  • EPS
  • CGON N/A
  • RNG N/A
  • Revenue
  • CGON $662,000.00
  • RNG $2,428,240,000.00
  • Revenue This Year
  • CGON N/A
  • RNG $5.82
  • Revenue Next Year
  • CGON $25,206.93
  • RNG $5.51
  • P/E Ratio
  • CGON N/A
  • RNG N/A
  • Revenue Growth
  • CGON 224.51
  • RNG 7.78
  • 52 Week Low
  • CGON $14.80
  • RNG $20.59
  • 52 Week High
  • CGON $40.47
  • RNG $42.19
  • Technical
  • Relative Strength Index (RSI)
  • CGON 59.29
  • RNG 70.54
  • Support Level
  • CGON $25.51
  • RNG $26.58
  • Resistance Level
  • CGON $27.28
  • RNG $27.66
  • Average True Range (ATR)
  • CGON 1.01
  • RNG 0.83
  • MACD
  • CGON 0.02
  • RNG 0.29
  • Stochastic Oscillator
  • CGON 89.23
  • RNG 91.21

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About RNG RingCentral Inc.

RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.

Share on Social Networks: